DIRMC

Through this database, users can access all molecular characteristics related to cancer immunotherapy, including drugs approved by FDA, EMA, NMPA , etc., drugs that are still in clinical development stage, and the prediction of potential target relationship of immunotherapy.

Please do not hesitate to contact us if you have any question huyang@hit.edu.cn.

Please cite the database as
Yue Liu‡, Yuhuan Zhou‡, Haoyan Wang, Junyi Li*, Yang Hu*, Yadong Wang*, DIRMC: A Database of Immunotherapy-Related Molecular Characteristics, Database.

DIRMC was developed at School of Computer Science and Technology, Harbin Institute of Technology. If you have a source of information related to the new discoveries in cancer immunotherapy that you would like us to incorporate, please contact us at huyang@hit.edu.cn.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Liu and Professor. Hu.